In human prostate cancer, CCNE2 expression is elevated in tumor tissues (Wu et al., 2009, and when PTEN, which is conventionally lowly expressed in prostate cancer cells, is reintroduced, CCNE2 is blocked and results in cycle G(1) arrest (Macdonald et al., 2014). Here, CCNE2 is linked to neoplasm.